Loading clinical trials...
Loading clinical trials...
A Phase I/II Dosing Study of the Safety and Antiretroviral Activity of Hydroxyurea Alone and in Combination With ddI Compared With ddI Alone in Subjects With HIV Infection
Conditions
Interventions
Hydroxyurea
Didanosine
Locations
18
United States
Univ of California / San Diego Treatment Ctr
San Diego, California, United States
Stanford at Kaiser / Kaiser Permanente Med Ctr
San Francisco, California, United States
Stanford Univ Med Ctr
Stanford, California, United States
Harbor UCLA Med Ctr
Torrance, California, United States
Univ of Colorado Health Sciences Ctr
Denver, Colorado, United States
Johns Hopkins Hosp
Baltimore, Maryland, United States
Completion Date
January 1, 2000
Last Updated
November 1, 2021
NCT04142047
NCT06694805
NCT07428330
NCT05398185
NCT07225530
NCT07429864
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions